rrent status of maintenance therapy for advanced ovarian cancer Review (5808) Total Article Views Authors: Joanie Mayer Hope, Stephanie V Blank Published Date November 2009 Volume 2009:1 Pages 173 - 180 DOI: http://dx.doi.org/10.2147/IJWH.S4661 Joanie Mayer Hope, Stephanie V Blank New York University School of Medicine, Division of Gynecologic Oncology, New York NY, USA Abstract: Even after countered with and responding to maximal surgical and chemotherapy efforts, advanced ovarian cancer usually ultimately recurs. One strategy employed to forestall recurrence is maintenance chemotherapy, an extension of treatment following a complete response to conventional measures. Many agents have been studied and many more are currently under investigation in maintenance regimens. While phase III data suggest that taxane maintenance prolongs progression-free survival, no overall survival benefit has been established. This article reviews the current status of maintenance therapy for advanced ovarian cancer, including phase III evidence and new and upcoming trials.